Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Haleon PLC ( (GB:HLN) ).
Haleon PLC announced the purchase of 814,534 ordinary shares for cancellation as part of its share buyback program. This move is part of the company’s strategy to manage its share capital and potentially enhance shareholder value, impacting the number of shares with voting rights and aligning with regulatory requirements.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC demonstrates a robust financial foundation with strong profitability and cash flow, supporting its growth outlook. Positive market momentum and strategic initiatives like share buybacks enhance investor confidence. However, valuation concerns and external challenges such as currency headwinds and market conditions necessitate cautious optimism.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. Its diverse product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands like Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 27,490,889
Technical Sentiment Signal: Buy
Current Market Cap: £36.66B
For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.